We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Napo Pharm.Regs | LSE:NAPL | London | Ordinary Share | COM USD0.0001 REGS |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.35 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.35 | GBX |
Napo Pharm.Regs (NAPL) Share Charts1 Year Napo Pharm.Regs Chart |
|
1 Month Napo Pharm.Regs Chart |
Intraday Napo Pharm.Regs Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/9/2008 | 11:37 | Napo with Charts & News | 156 |
| 17/4/2008 | 16:46 | Napo Pharmaceuticals | 10 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 25/6/2008 16:42 by groats118 Nice, tick up before close. Very interesting!U got a target price for these? |
Posted at 25/6/2008 14:18 by monis I don't know they are buys, I said trades not buys. They do seem strange but if they are sells why no drop in price? I don't know how to interpret them. The 75,000 looks like a buy though. |
Posted at 25/6/2008 14:12 by groats118 MONISHow do you know they are buys? I bought £1200 worth a couple of days back and had to pay full offer price, I can't see how they getting mid-price for that quantity. I would say they are sells |
Posted at 23/6/2008 10:43 by monis Napo Pharma raises $2.1 mln net from convertible debt and share issuesLONDON (Thomson Financial) - Napo Pharmaceuticals Inc. said it has raised around $2.1 million gross through the issue of convertible debt and shares. The company also said it has now progressed commercial license talks with at least two potential partners for its crofelemer diarrhoea treatment. "We are pleased to announce this fundraising and the financial strength it provides Napo to complete our corporate licensing discussions while continuing with the progress of our final Phase 3 clinical trial for CRO-HIV and all NDA related activities," chief executive Lisa Conte said. TFN.newsdesk@thomson bsu/slm |
Posted at 17/6/2008 16:02 by monis 12p now to buy 10,500 shares. Above the offer price. |
Posted at 15/5/2008 19:34 by monis This TFN explains the link up between the two companies.Napo Pharma says recent shr price drop undervalues co, disregards trial results LONDON (Thomson Financial) - Napo Pharmaceuticals Inc. said the recent stock price drop dramatically undervalues the company, adding the fall in its share price places an unrealistic value on Napo and disregards the recently announced trial results. The pharma company had earlier said it received positive results from Phase 2 trials for its crofelemer (CRO-ID )treatment of acute adult infectious diarrhoea which was conducted by its licensee partner, Glenmark Pharmaceuticals Ltd. Glenmark reported crofelemer was well tolerated and showed significant improvements in all the primary endpoints -- stool weight, duration, frequency and consistency; additional endpoints included degree of patient dehydration and reduction in gastrointestinal index score. |
Posted at 08/5/2008 10:52 by monis 21 April 2008Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. The statistically significant results on crofelemer in the treatment of acute infectious diarrhoea have infused our on-going corporate partner and grant discussions with the opportunity to represent a potential dual indication approach to filings for regulatory approvals for crofelemer next year-chronic diarrhoea in people living with HIV/AIDS and acute infectious diarrhoea. This approach may potentially increase the likelihood of regulatory approval for at least one indication of crofelemer, it may also expand the available patient populations that might benefit from crofelemer, as well as increasing the target market size." |
Posted at 08/5/2008 09:58 by monis Up again. Share awards seem to me to state that directors don't get the shares unless the share price reaches $3.50 that is about a 1 pound seventy share price. So huge potential upside still. Of cause DYOR.It now just 9p! |
Posted at 29/4/2008 16:13 by monis From recent update. Make of it what you will....Management have plans to raise additional funds, which include: the out-license of certain rights to crofelemer including the indications of CRO-HIV, CRO-IBS,CRO-ID and CRO-PED in the United States and other western territories; as well as certain rights to NP-500, in exchange for a licensing fee(s)... ...Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." ... Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. Of cause DYOR. |
Posted at 23/4/2008 15:11 by monis From recent update. Make of it what you will....Management have plans to raise additional funds, which include: the out-license of certain rights to crofelemer including the indications of CRO-HIV, CRO-IBS,CRO-ID and CRO-PED in the United States and other western territories; as well as certain rights to NP-500, in exchange for a licensing fee(s)... ...Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." ... Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. Of cause DYOR. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
